MA53636A - Agent de traitement de troubles dermatologiques - Google Patents

Agent de traitement de troubles dermatologiques

Info

Publication number
MA53636A
MA53636A MA053636A MA53636A MA53636A MA 53636 A MA53636 A MA 53636A MA 053636 A MA053636 A MA 053636A MA 53636 A MA53636 A MA 53636A MA 53636 A MA53636 A MA 53636A
Authority
MA
Morocco
Prior art keywords
agent
treatment
dermatological disorders
dermatological
disorders
Prior art date
Application number
MA053636A
Other languages
English (en)
Inventor
Laura Calzà
Bruno Pietro Imbimbo
Gino Villetti
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA53636A publication Critical patent/MA53636A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MA053636A 2018-09-17 2019-09-17 Agent de traitement de troubles dermatologiques MA53636A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18194930 2018-09-17
EP18203665 2018-10-31

Publications (1)

Publication Number Publication Date
MA53636A true MA53636A (fr) 2021-12-22

Family

ID=67989007

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053636A MA53636A (fr) 2018-09-17 2019-09-17 Agent de traitement de troubles dermatologiques

Country Status (11)

Country Link
US (2) US20220064243A1 (fr)
EP (1) EP3852785A1 (fr)
JP (2) JP2022502359A (fr)
KR (1) KR20210061388A (fr)
CN (1) CN113226350B (fr)
AU (1) AU2019343514B2 (fr)
BR (1) BR112021003820A2 (fr)
CA (1) CA3111158A1 (fr)
MA (1) MA53636A (fr)
MX (1) MX2021002983A (fr)
WO (1) WO2020058217A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115942951A (zh) * 2020-07-27 2023-04-07 人类细胞公司 Ngf变体，制备，组合物和治疗用途
US20240024216A1 (en) * 2021-01-06 2024-01-25 The Penn State Research Foundation Methods and materials for treating hair loss
US12268677B2 (en) 2022-04-27 2025-04-08 The Penn State Research Foundation 4-aminopyridine (4-AP) and bone morphogenetic protein 2 (BMP-2)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0994188B1 (fr) 1998-10-09 2004-01-07 Scil proteins GmbH Procédé d'obtention du NGF-bêta biologiquement actif
US7517528B2 (en) 2002-03-12 2009-04-14 Bio-Click Technologies, Ltd. Method and composition for treating skin wounds with epidermal growth factor
ITRM20060367A1 (it) * 2006-07-13 2008-01-14 Lay Line Genomics Spa Muteine del hngf usi terapeutici e composizioni farmaceutiche
WO2010128519A1 (fr) 2009-05-04 2010-11-11 Kumar C Jairaj Procédé de détection d'une neuropathie et de prédiction de l'apparition d'un ulcère du pied chez des êtres humains atteints de pahtologies telles que le diabète sucré
CN104203264B (zh) 2011-12-19 2018-08-28 瓦克化学有限公司 新型proNGF突变体及其在生产β-NGF中的用途
US20180086805A1 (en) * 2016-05-20 2018-03-29 Chiesi Farmaceutici S.P.A. proNGF mutants and uses thereof for the preparation of NGF mutants

Also Published As

Publication number Publication date
US20250277010A1 (en) 2025-09-04
KR20210061388A (ko) 2021-05-27
MX2021002983A (es) 2021-05-14
CA3111158A1 (fr) 2020-03-26
WO2020058217A1 (fr) 2020-03-26
JP2025125558A (ja) 2025-08-27
CN113226350A (zh) 2021-08-06
CN113226350B (zh) 2024-09-10
BR112021003820A2 (pt) 2021-05-25
EP3852785A1 (fr) 2021-07-28
US20220064243A1 (en) 2022-03-03
AU2019343514B2 (en) 2025-09-25
JP2022502359A (ja) 2022-01-11
AU2019343514A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
DK3731772T3 (da) Systems for the treatment of disease states and disorders
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3448398A4 (fr) Compositions et méthodes pour le traitement de troubles cutanés
EP3481387A4 (fr) Methodes et compositions pour le traitement de troubles épileptiques
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3328492A4 (fr) Dispositifs de photothérapie pour le traitement de troubles dermatologiques du cuir chevelu
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
IL288001A (en) Compounds for the treatment of neurodegenerative and metabolic disorders
EP3411380A4 (fr) Composés destinés au traitement de troubles ou de maladies oculaires
EP4045037C0 (fr) Hétéroaryl-biphénylamines pour le traitement de maladies pd-l1
IL286340A (en) Topical formulations for treatment of peripheral neuropathies
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
EP3328864A4 (fr) Composés et compositions thérapeutiques pour le traitement de troubles sociaux et de troubles liés à la toxicomanie
EP3352749A4 (fr) Composés et compositions pour le traitement de troubles oculaires
EP3606520A4 (fr) Inhibiteurs de l'activité de la déshydrogénase à chaîne courte pour le traitement des troubles coronaires
EP3445352A4 (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
EP3400061A4 (fr) Système de photothérapie pour le traitement d'affections nasales
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
MA47207A (fr) Composés utiles pour le traitement de troubles du tractus digestif
EP3672587A4 (fr) Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques
EP3766497A4 (fr) Médicament pour le traitement de la toux
EP3481958A4 (fr) Procédés et compositions de traitement de troubles et de maladies impliquant rdh12
MA49140A (fr) Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques